The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly
expanded. There is a need to develop noninvasive biomarkers to guide treatment. We …

Purpose: Although novel agents targeting the androgen–androgen receptor (AR) axis have
altered the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC) …

Background There is an urgent need to identify biomarkers to guide personalized therapy in
castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen …

PURPOSE Androgen receptor (AR) gene alterations, including ligand-binding domain
mutations and copy number (CN) gain, have yet to be fully established as predictive markers …

The therapeutic landscape of prostate cancer has expanded rapidly over the past 10 years,
and there is now an even greater need to understand the biological mechanisms of …

BACKGROUND Coding mutations in the AR (androgen receptor) gene have been identified
in tissue samples from patients with advanced prostate cancer and represent a possible …

Importance The molecular landscape underpinning response to the androgen receptor (AR)
antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer …

Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-
naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is …

Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary
hormone treatment but emerge with castration resistance. To determine AR gene status …

Somatic genetic alterations including copy number and point mutations in the androgen
receptor (AR) are associated with resistance to therapies targeting the androgen/AR axis in …